[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Applied Biology, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":187},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,62,90,110,132,151,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100623491","phase-1-clinical-study-of-da-020-for-the-treatment-of-chemotherapy-induced-alopecia-100623491",false,"NCT07397325","Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia",[27,28],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[27,30],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2026-04-08",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":20},"2026-04-16",{"date":39,"type":20},"2026-12-07",{"name":41,"class":42},"Applied Biology, Inc.","INDUSTRY",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":48,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":43},"100623876","early-phase-1-pharmacokinetic-study-of-da-020-100623876","NCT07402330","Pharmacokinetic Study of DA-020","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"55 Years",{"count":19,"type":20},[54],"EARLY_PHASE1",[27,28],[27,30],{"date":34,"type":35},{"date":37,"type":20},{"date":60,"type":20},"2026-11-30",{"name":41,"class":42},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":68,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100565951","phase-2-clinical-study-of-da-001-as-a-treatment-for-hair-shedding-reduction-and-hair-re-growth-100565951","NCT06648850","Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with telogen effluvium\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits","ALL",{"count":70,"type":20},1120,[24,72],"PHASE3","The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth",[75,76,77,78,79,80],"Telogen Effluvium","Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia","Male Pattern Baldness","Androgenetic Alopecia","Androgenetic Alopecia (AGA)",[82,83],"Hair Shedding","hair growth",{"date":34,"type":35},{"date":86,"type":20},"2026-05-01",{"date":88,"type":20},"2027-04-26",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":94,"conditions":98,"keywords":99,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100595545","early-phase-1-pharmacokinetic-study-of-topical-phenylephrine-100595545","NCT07033845","Pharmacokinetic Study of Topical Phenylephrine",{"count":96,"type":20},24,[54],[27,28],[27,30],"RECRUITING","2025-09-30",{"date":103,"type":35},"2025-10-03",{"date":105,"type":35},"2025-06-30",{"date":107,"type":20},"2025-12-28",{"name":41,"class":42},1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":68,"minAge":116,"maxAge":17,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100605733","phase-1-clinical-study-of-mtor-inhibitor-as-a-treatment-for-grey-hair-canities-100605733","NCT07166354","Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)","Inclusion Criteria:\n\n* Age 30 to 65\n* Diagnosed with Grey Hair (Canities)\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in CS-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits","30 Years",{"count":118,"type":20},100,[23,24],"Clinical Study to Assess the Safety and Efficacy of CS-002 (mTOR inhibitor) as a treatment for Canities (Grey Hair)",[122,123],"Canities","Grey Hair","2025-09-03",{"date":126,"type":35},"2025-09-10",{"date":128,"type":20},"2025-10-01",{"date":130,"type":20},"2027-09-15",{"name":41,"class":42},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":109},"100574689","phase-3-clinical-study-of-da-007-for-the-treatment-of-chemotherapy-induced-alopecia-100574689","NCT06762548","Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia",{"count":138,"type":20},140,[72],"Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia",[27,28],[27,30],"2025-05-22",{"date":145,"type":35},"2025-05-23",{"date":147,"type":20},"2025-10-10",{"date":149,"type":20},"2026-11-06",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":68,"minAge":116,"maxAge":17,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":4},"100573365","phase-3-clinical-study-of-cs-001-as-a-treatment-for-canities-grey-hair-100573365","NCT06745336","Clinical Study of CS-001 As a Treatment for Canities (Grey Hair)",{"count":157,"type":20},240,[72],"Clinical Study to Assess the Safety and Efficacy of CS-001 as a treatment for Canities (Grey Hair)",[122,123],"2024-12-19",{"date":163,"type":35},"2024-12-24",{"date":165,"type":20},"2025-06-15",{"date":130,"type":20},{"name":41,"class":42},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":68,"minAge":16,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100554656","phase-3-clinical-study-of-da-002-and-da-005-as-a-treatment-for-hair-loss-100554656","NCT06501924","Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with androgenetic alopecia\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-002 or DA-005\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits",{"count":175,"type":20},516,[72],"The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).",[79,179,78],"Female Pattern Baldness","2024-12-17",{"date":161,"type":35},{"date":183,"type":20},"2025-01-15",{"date":185,"type":20},"2025-12-12",{"name":41,"class":42},""]